

7 January 2019

Our Ref: RFI 26334

Dear

**Freedom of Information Act 2000
Information in Relation to Cancer Services**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 5 December 2018.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**Catherine Treanor
Information Governance Assistant**

Q1. Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care?

A1. The information requested is not held centrally in relation to all existing patients who are being treated for metastatic breast cancer.

To obtain this information would require a manual review of paper records and a review of a number of electronic systems.

Given the number of records concerned, this would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this letter acts as a Refusal Notice.

Q2. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonefos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**
- **denosumab (Xgeva)**

A2. Please see Table 1 below.

Table 1

Treatment	Comment
disodium pamidronate (Aredia)	None
ibandronic acid or ibandronate (Bondronat)	This is issued from primary care
sodium clodronate (Bonefos, Clasteon, Loron)	This is issued from primary care
zoledronic acid or zoledronate (Zometa)	4 in total, cannot break down into metastatic and adjuvant.
denosumab (Xgeva)	42

Q3. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonefos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**

A3. Please see Table 2 below.

Table 2

Treatment	Comment
disodium pamidronate (Aredia)	None
ibandronic acid or ibandronate (Bondronat)	This is issued from primary care
sodium clodronate (Bonefos, Clasteon, Loron)	This is issued from primary care
zoledronic acid or zoledronate (Zometa)	4 in total, cannot break down into metastatic and adjuvant

Q4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care?

A4. The information requested is not held centrally in relation to all existing patients who are being treated for metastatic lung cancer.

To obtain this information would require a manual review of paper records and a review of a number of electronic systems.

Given the number of records concerned, this would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this letter acts as a Refusal Notice.

Q5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonefos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**
- **denosumab (Xgeva)**

A5. Please see Table 3 below.

Table 3

Treatment	Comment
disodium pamidronate (Aredia)	none
ibandronic acid or ibandronate (Bondronat)	This is issued from primary care
sodium clodronate (Bonefos, Clasteon, Loron)	This is issued from primary care
zoledronic acid or zoledronate (Zometa)	1
denosumab (Xgeva)	1

Q6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care?

A6. This service is not provided by the Trust.

Q7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonefos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**
- **denosumab (Xgeva)**

A7. Not applicable.